Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.

@article{Mosedale2017EditorsHC,
  title={Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.},
  author={Merrie Mosedale and Yunjung Kim and William John Brock and Sharin E. Roth and Tim Wiltshire and J. Scott Eaddy and Gregory R Keele and Robert W Corty and Yuying Xie and William Valdar and Paul B Watkins},
  journal={Toxicological sciences : an official journal of the Society of Toxicology},
  year={2017},
  volume={156 2},
  pages={
          438-454
        }
}
Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population. To identify risk factors and mechanisms underlying tolvaptan DILI, 8 mice in each of 45 strains of the genetically diverse Collaborative Cross (CC) mouse population were treated with a single oral dose of either tolvaptan or vehicle. Significant… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 5 times. VIEW TWEETS